Bayer's Pipeline Push Meets a Missouri Deadline: Kerendia, Canola, and a EUR 3 Billion Debt Trim
Published on 09/13/2026 at 13:20 | Editorial boerse-global.de
Bayer's week began with a courtroom calendar entry, not a laboratory result. A hearing in Missouri on September 14 will weigh final approval of the company's glyphosate settlement — a proceeding tied to a package worth as much as USD 7.25 billion. Everything else the German life-sciences group has announced lately, from a kidney-drug filing to a canola partnership, sits in the shadow of that single date.
Kerendia's Second Act
The most consequential pipeline news concerns finerenone, sold as Kerendia. The Phase III FIND-CKD trial delivered positive results in late August for patients with non-diabetic chronic kidney disease, and Bayer has since filed for regulatory approval in China, the EU, and Japan. Adding an indication to an already-marketed molecule matters because it spares the group the long, costly early-stage development gauntlet — a useful lever given that pharma revenue slipped 3.6% in the second quarter under the weight of higher marketing spend.
Oncology has been carrying its own weight. The FDA granted accelerated approval last Thursday to sevabertinib, branded Hyrnuo, for first-line treatment of HER2-mutant non-small cell lung cancer. In the supporting Phase I/II SOHO-01 study, the drug produced a 75% response rate across 69 previously treated patients; it had already won clearance in Japan. Nubeqa, meanwhile, contributed EUR 820 million in second-quarter sales. Add June's acquisition of Perfuse Therapeutics, which brought in the glaucoma and diabetic retinopathy candidate PER-001, and the picture is of a pipeline advancing on several fronts at once.
Cardiology is getting attention too: on Wednesday, Bayer launched a Phase II trial of an investigational GIRK4 inhibitor in patients with atrial fibrillation.
Should investors sell immediately? Or is it worth buying Bayer?
A Canola Bet Beyond the Usual Crop-Chemistry Playbook
Away from the lab, Bayer has struck a commercial agreement with Finland's Neste Oyj centered on Newgold Winter Canola, a rapeseed variety the two partners intend to scale for biofuel production. No volume or revenue targets were disclosed, but the strategic signal is clear — Bayer wants growth avenues that don't run through classic pesticide and seed sales. The crop-science division had already used its early-September investor day to showcase progress on its "ten blockbusters" strategy, with Plenexos and the Preceon Smart Corn System already on the market. How quickly Newgold Winter Canola scales in practice will determine whether the Neste tie-up becomes a genuine growth driver.
The Balance Sheet Is Straightening Out
Half-year figures published in early August show a company steadily tidying its finances. Revenue rose 3.3% on a currency- and portfolio-adjusted basis to EUR 24.277 billion, while adjusted EBITDA climbed 6.6% to EUR 6.597 billion. The standout item: Bayer cut its net financial debt guidance from an original EUR 32–33 billion to EUR 29–30 billion after an agreement with Apollo opened up additional financial room.
Analysts See Room to Run; the Market Shrugs
Barclays raised its Bayer price target to EUR 70 on September 8, keeping an "Overweight" rating. Deutsche Bank followed two days later, reiterating "Buy" with a EUR 60 target. Both imply substantial upside from current levels. The stock has yet to respond in kind. Friday's close came in at EUR 48.19, down 0.6% on the day, with a 1.3% decline accumulated over the past seven trading sessions. Year-to-date the shares are still up 30%, and 67% over twelve months, though they sit roughly 11% below the 52-week high of EUR 53.86 touched in early July.
That muted reaction to bullish analyst calls suggests investors remain cautious until the Roundup litigation is fully resolved. The coming weeks will test whether operational momentum in pharma and agriculture is enough to pull sentiment along with it — or whether a Missouri judge's signature still holds the louder voice.
Ad
Bayer Stock: New Analysis - 13 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
